Drug intelligence / Profile preview

crataegus special extract WS 1442

Development stage: Phase 3
Lead developer: Schwabe
Administration: Oral

Overview

Crataegus special extract WS 1442 is a standardized ethanolic (45% w/w) extract from hawthorn (Crataegus species) leaves and flowers. It contains 18.75% oligomeric procyanidins (OPC) as the primary active components. The extract exhibits cardioprotective properties through multiple mechanisms including positive inotropic effects, vasodilation, antioxidant activity, and prevention of endothelial hyperpermeability.

Brand names: CrataeguttCardioMaxCrataegutt novo 450CardiplantCrataegisanFarosKorodinLI 132LI132LI-132
Other names: Crataegus special extract ws 1442Hawthorn extract ws 1442

Targets

SOCE (Calcium release-activated calcium channel)NOS3 (eNOS)ATP2A (Sarcoplasmic reticulum Ca2+-ATPase)IP3R (Inositol Trisphosphate Receptor)

Beyond the preview

Go deeper on crataegus special extract WS 1442.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on crataegus special extract WS 1442.

Explore the full profile